CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Times cited: 21
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic proceedings. 2015 Information Resource GET IT
- Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia & lymphoma. 2015 Academic Article GET IT